This inventor holds 2 USPTO granted patents. Top assignees: Glaxosmithkline LLC, Smithkline Beecham Corporation. Active years: 2007-2010.
Company Filing History:
Years Active: 2007-2010
Title: Jacob Bongers: Innovator in Cancer Treatment
Introduction
Jacob Bongers is a notable inventor based in King of Prussia, PA (US). He has made significant contributions to the field of cancer treatment through his innovative research and patented methods. With a total of 2 patents, Bongers has focused on enhancing the efficacy of cancer therapies.
Latest Patents
Bongers' latest patents include a method of treating cancer by administering conjugates comprising human IL-18 and substitution mutants thereof. This method involves the use of human interleukin-18 (IL-18) polypeptides that are conjugated to water-soluble polymers at specific sites on the human IL-18 protein. The conjugates retain biological activity and demonstrate enhanced properties compared to unconjugated cytokines. His other patent also revolves around the conjugation of human IL-18 and its substitution mutants to water-soluble polymers, further emphasizing the innovative approach to cancer treatment.
Career Highlights
Throughout his career, Jacob Bongers has worked with prominent companies such as SmithKline Beecham Corporation and GlaxoSmithKline LLC. His experience in these organizations has contributed to his expertise in the field of biotechnology and pharmaceuticals.
Collaborations
Bongers has collaborated with notable professionals in his field, including Narendra B. Bam and Robert B. Kirkpatrick. These collaborations have likely enriched his research and development efforts.
Conclusion
Jacob Bongers stands out as an inventor dedicated to advancing cancer treatment through innovative methods and collaborations. His work continues to impact the medical field positively.